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Purpose. Increasing body mass index (BMI) is associated with higher risk prostate cancer (PC) at presentation. Whether increasing
BMI also prompts earlier salvage androgen suppression therapy (sAST) is unknown. Materials and Methods. Between 1995 and
2001, 206 men with unfavorable risk PC were treated with radiation therapy (RT) or RT and six months of androgen suppression
therapy in a randomized controlled trial (RCT). 108 sustained PSA failure; 51 received sAST for PSA approaching 10 ng/mL; 49
with BMI data comprised the study cohort. A multivariable Cox regression analysis identified pretreatment factors associated with
earlier sAST receipt.Results. Increasing BMI prompted earlier sAST (median years: 3.7 for overweight/obese, 6.9 for normal weight;
adjusted hazard ratio (AHR): 1.11; 95% CI: 1.04, 1.18; 𝑃 = 0.002) as did high versus other risk PC (median: 3.2 versus 5.2 years; AHR:
2.01; 95% CI: 1.05, 3.83; 𝑃 = 0.03). Increasing median time to sAST was observed for overweight/obese men with high versus other
risk PC and for normal-weight men with any risk PC being 2.3, 4.6, and 6.9 years, respectively (𝑃 < 0.001 for trend). Conclusion.
Increasing BMI was associated with earlier sAST. A RCT evaluating whether BMI reduction delays or eliminates need for sAST is
warranted.
1. Introduction
Prostate cancer (PC) is themost commonly diagnosed cancer
in males and the second most common cause of cancer death
inmen after lung cancer [1].The prevalence of obesity inUSA
population is increasing and is linked with increased overall
mortality [2, 3]. Higher body mass index (BMI) has been
shown in multiple studies of men with PC being associated
with increased PC-specific mortality [4, 5], increased risk
of PSA failure following radical prostatectomy [6, 7] or
external beam radiation therapy (RT) [8, 9], higher risk
disease at presentation [10–12], and higher likelihood of
castrate-resistant disease or metastases following androgen
suppression therapy (AST) [13], after adjusting for known risk
factors.
Possible explanations for why increased BMI could
promote more aggressive disease [14] include diet-induced
hyperinsulinemia leading to tumor growth [5, 15, 16],
increased estradiol and low testosterone serum concentra-
tions in obese men producing more aggressive, testosterone
independent PC, since such cancers would have arisen in
an environment where testosterone was low [17, 18], chronic
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subclinical inflammation [19], or functional single nucleotide
polymorphisms [20].
To date, a prospective assessment in the context of a
randomized controlled trial (RCT) has not been performed
that investigates whether a relationship exists between BMI
at randomization and the time to salvage AST (sAST),
following RT with or without six months of AST for men
with localized intermediate or high risk PC where sAST
was administered if the PSA approached a prespecified level.
Therefore, the purpose of this study was to examine the
effect of pretreatment BMI on the time to sAST, adjusting for
known PC prognostic factors, age at PSA failure, comorbidity
using the Adult Comorbidity Evaluation- (ACE-) 27 metric,
[21] and initial treatment in the setting of a RCT where
patients with unfavorable localized and locally advanced PC
were treated with RT or RT and six months of AST.
2. Materials and Methods
2.1. Patient Population and Treatment. Between December
7, 1995, and December 27, 2001, 206 men were enrolled
on a RCT comparing the impact on overall survival of
treatment with RT with or without six months of AST.
Details of the study design and inclusion criteria have been
reported previously [22]. While the study cohort consisted
primarily of men with NCCN intermediate and high risk
disease, men with low risk disease were included if they
had evidence on a endorectal magnetic resonance imaging
study of seminal vesicle invasion or extracapsular extension
(T3 disease). Of 206 men, 108 sustained a PSA failure (as
determined by three consecutive rises in serum PSA over
nadir) and 51 of these received sAST. Of the 51, two patients
did not have baseline BMI data at presentation. Therefore
the study cohort consisted of the remaining 49 men. sAST
was administered between October 31, 1996, and February
9, 2011, and consisted of a lifelong LHRH agonist with or
without an antiandrogen (𝑁 = 43) or bilateral orchiectomy
(𝑁 = 6). Clinical or biochemical failure following sAST
was managed with further hormone manipulation prior to
systemic chemotherapy.This studywas approved by theDana
Farber/Harvard Cancer Center Institutional Review Board.
2.2. Follow-Up and Determination of Cause of Death. Fol-
lowing the end of treatment, men were followed every three
months for the first two years, every six months for the
subsequent three years, and annually thereafter. At each
follow-up a serumPSAwas obtained and a digital rectal exam
was performed. sAST was administered as per protocol when
and if the PSA level approached 10 ng/mL. To be considered
to have died from PC, a patient needed to have radiographic
documentation of metastatic disease and have experienced a
rising PSA despite treatment with sAST, secondary hormonal
maneuvers, and systemic chemotherapy.
2.3. Statistical Methods
2.3.1. Description of Study Cohort. Descriptive statistics were
used to create Table 1, which contains the distribution at
randomization of the patients’ clinical characteristics who
underwent sAST. The median (IQR) PSA measured most
closely prior to receipt of sAST was 9.7 ng/mL (7.6, 12.1).
2.3.2. Time to sAST Analysis. The primary endpoint of this
study was time to sAST use. A multivariable Cox regression
analysis [23] was used to ascertain whether clinical factors at
randomization were associated with increased risk of receipt
of sAST. For the purpose of this study, time zero was the date
of randomization. Clinical factors evaluated included age,
BMI, and percent positive biopsies as continuous covariates
and treatment received, ACE-27 comorbidity score, and
NCCN risk group as categorical covariates. Because of the
known interaction between hormonal therapy and comor-
bidity score, an interaction term between treatment received
and comorbidity score was included in the model [22]. The
baseline groups for the categorical covariates were as follows:
treatment with RT and AST, no or minimal comorbidity, and
intermediate risk PC. Unadjusted and adjusted hazard ratios
and the associated 95 percent confidence intervals, as well as
𝑃 values, were calculated for each covariate [23]. A two-sided
𝑃 value of less than 0.05 was considered significant.
2.3.3. Estimates of Freedom from Receipt of sAST. Kaplan-
Meier estimates [24] of freedom from the receipt of sAST
were calculated and displayed graphically, stratified by
the significant covariates shown to be associated with an
increased risk of receipt of sAST on multivariable analysis.
Pairwise comparisons of these estimates were performed
using a log-rank test [25]. Correction for multiple compar-
isons (𝑛 = 3) was performed using a Bonferroni correction
[26] such that a significant 𝑃 value was now less than 0.017.
SAS version 9.3 (SAS Institute, Cary, NC) was used for all
statistical analyses.
3. Results
3.1. Description of Study Cohort. Table 1 illustrates the distri-
bution of clinical characteristics at randomization for the 49
men who underwent sAST. The majority of these men were
healthy (80% ACE-27 comorbidity score no or minimal) and
the vast majority (79%) had Gleason 7 or higher PC. Of note,
84% of men had a BMI of at least 25 kg/m2 classifying them
as overweight or obese, and only 31% were randomized to
receive RT and six months of AST as initial treatment.
3.2. Time to sAST Analysis. Themedian (IQR) time to receipt
of sAST was 4.0 years (2.3, 6.2). As shown in Table 2,
increasing BMI was associated with earlier administration of
sAST (median time 3.7 versus 6.9 years for overweight or
obese versus normal weight; adjusted hazard ratio (AHR):
1.11; 95% CI: 1.04, 1.18; 𝑃 = 0.002). In addition, men with high
versus other risk PC (3.2 versus 5.2 years; AHR: 2.01; 95% CI:
1.05, 3.83;𝑃 = 0.03) received sAST sooner as didmen initially
randomized to RT (AHR: 2.30; 95% CI: 1.02, 5.18; 𝑃 = 0.05).
3.3. Estimates of Freedom from Receipt of sAST. Figure 1
illustrates the significant impact that both increasing BMI
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Table 1: Description of the 49 men in the study cohort who
underwent sAST stratified by clinical factors at randomization and
initial treatment.
Clinical factor
Age, median (IQR), yr 72.0 (68.9, 75.5)
PSA, median (IQR), ng/mL 12.1 (7.90, 20.0)
PSA
<4 3 (6%)
4–10 15 (31%)
10–20 18 (37%)
>20 13 (27%)
Gleason score
5-6 10 (20%)
7 28 (57%)
8–10 11 (22%)
ACE-27 comorbidity score
No or minimal 39 (80%)
Moderate or severe 10 (20%)
1992 AJCC clinical stage
T1c 18 (37%)
T2a 8 (16%)
T2b 23 (47%)
BMI, median (IQR), kg/m2 27.4 (26.0, 30.2)
BMI
<18.5 (underweight) 0 (0%)
18.5–24.9 (normal) 8 (16%)
25.0–29.9 (overweight) 28 (57%)
≥30.0 (obese) 13 (27%)
Percent positive biopsies, median (IQR) 50.0 (33.3, 66.7)
Percent positive biopsies:
<50% 19 (39%)
≥50% 30 (61%)
2013 NCCN risk group
Lowa or intermediate risk 30 (61%)
High risk 19 (39%)
Initial treatment received
RT only 34 (69%)
RT + AST 15 (31%)
Abbreviations: BMI: body mass index, RT: radiation therapy, AST: androgen
suppression therapy, sAST: salvage androgen suppression therapy, ACE:
Adult Comorbidity Evaluation, and IQR: interquartile range.
aAs described in Section 2, men with low risk disease (calculated using
PSA level, Gleason score, and clinical stage) were included if they had
radiographic evidence of T3 disease (extracapsular extension or seminal
vesicle invasion). In this study, two men were included who met these
criteria.
and NCCN risk group have on the risk of receiving sAST.
Specifically, increasingmedian time to sASTwas observed for
overweight/obese men with high versus other risk PC and for
normal-weight men with any risk PC being 2.3, 4.6, and 6.9
years, respectively (𝑃 < 0.001 for trend).
With respect to pairwise comparisons, men who were
overweight or obese (BMI > 25 kg/m2) at randomizationwith
high risk disease were at highest risk for receipt of sAST
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Figure 1: Kaplan-Meier estimates of freedom from receipt of salvage
androgen suppression therapy stratified by risk group and the BMI
cut point for the upper limit of normal-weight BMI < 25 kg/m2 with
any risk disease versus BMI> 25 kg/m2 with low or intermediate risk
disease (𝑃 = 0.005), BMI > 25 kg/m2 with high risk disease versus
BMI > 25 kg/m2 with low or intermediate risk disease (𝑃 = 0.005),
and BMI > 25 kg/m2 with high risk disease versus BMI < 25 kg/m2
with any risk disease (𝑃 < 0.001).
followed by men who had BMI > 25 kg/m2 but low (with
radiographic T3 disease) or intermediate risk disease (𝑃 =
0.005 for comparison). By contrast, the most favorable group
was the men with BMI < 25 kg/m2 at randomization and
any risk disease (𝑃 = 0.005 for comparison with BMI >
25 kg/m2 and low or intermediate risk disease and 𝑃 < 0.001
for comparison with BMI > 25 kg/m2 and high risk disease).
Five year point estimates (95% CI) for freedom from receipt
of sAST for each of these groups ranging from least to most
favorable were 18.8% (4.6%, 40.2%), 44.0% (24.5%, 61.9%),
and 87.5% (38.7%, 98.1%).
4. Discussion
In this study we found that increasing BMI was associated
with a shorter time after randomization to receipt of sAST
in the setting of a prospective RCT where sAST adminis-
tration was required as per protocol if and when the PSA
level approached 10 ng/mL. In addition we demonstrated
the known association between shorter time to sAST and
treatment with RT only or in patients who present with
unfavorable risk PC. The clinical significance of our findings
is that by taking measures prior to diagnosis of PC to
reduce BMI—a modifiable risk factor—that more advanced
disease at presentation and higher biochemical recurrence
rates following initial treatment that are associated with a
high BMI [10–12] may be reduced or avoided [27].Therefore,
this study raises the testable hypothesis that modifying one’s
health prior to a diagnosis of PC through interventions that
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Table 2: Cox regression unadjusted and adjusted hazard ratios for clinical factors predicting for the risk of receipt of sAST.
Clinical factor Number of men Univariate analysis Multivariate analysis
HR (95% CI) 𝑃 value AHR (95% CI) 𝑃 value
Initial treatment
RT only 34 1.47 (0.74, 2.93) 0.27 2.30 (1.02, 5.18) 0.05
RT + AST 15 1.00 (Ref) — 1.00 (Ref) —
ACE-27 comorbidity score
None to minimal 39 1.00 (Ref) — 1.00 (Ref) —
Moderate to severe 10 1.32 (0.37, 4.72) 0.67 2.67 (0.60, 11.97) 0.20
Treatment × comorbidity score interaction 49 0.51 (0.11, 2.42) 0.39 0.14 (0.02, 1.05) 0.06
Age, yr 49 0.96 (0.91, 1.02) 0.17 0.97 (0.92, 1.04) 0.39
BMI, kg/m2 49 1.07 (1.00, 1.14) 0.04 1.11 (1.04, 1.18) 0.002
2013 NCCN risk group
Low or intermediate risk 30 1.00 (Ref) — 1.00 (Ref) —
High risk 19 1.56 (0.87, 2.82) 0.14 2.01 (1.05, 3.83) 0.03
Percent positive biopsies 49 1.00 (0.99, 1.01) 0.68 1.01 (0.99, 1.02) 0.35
Abbreviations: BMI: body mass index, RT: radiation therapy, AST: androgen suppression therapy, sAST: salvage androgen suppression therapy, ACE: Adult
Comorbidity Evaluation, IQR: interquartile range, HR: hazard ratio, and AHR: adjusted hazard ratio.
lower BMI could lead to less aggressive disease at presenta-
tion, lower recurrence rates, decreased need for sAST, and
therefore an overall better prognosis.
Several points require further discussion. First, previ-
ous studies have described the health benefits of a lower
BMI, specifically resulting in improvements in cardiovascular
risk factors (such as lower cholesterol and blood pressure),
glycemic control, and longevity [28, 29], in addition to known
associations of presentingwith lower risk PC, which portends
a better prognosis and likely avoidance of upfront and/or
sAST [30]. Given that AST administration also has been
associated with numerous adverse health events [31] includ-
ing weight gain that can lead to obesity [32], preventative
measures to reduce the risk of becoming obese stand to
improve overall health in addition to prognosis following a
diagnosis of PC.
While our study is limited by a sample size of 49
patients, the follow-up is sufficient to permit a demonstration
(Figure 1) of the independent impact that BMI has on the
subsequent time to sAST across NCCN risk groups [30]. Also
while this study focused on time to sAST, larger studies are
needed to validate whether BMI’s independent association
with a shorter time to sAST translates into an increased
risk of death due to PC and all-cause mortality. In addition,
an alternative hypothesis exists to explain the association
observed between increasing BMI and a shorter time to
sAST. Specifically, significant error in reproducibility of daily
treatment setup in men with elevated BMIs was noted in a
recent study by Millender and colleagues [33]. They found
that in three men with high BMIs, setup error could be
decreased through the use of fiducial marker placement
and daily imaging. The men in our study were treated in
an era before fiducial marker placement and daily imaging
and instead were treated using three-dimensional conformal
radiation therapy. Therefore, the data by Millender and
colleagues support the alternative explanation that the obese
men in our studymay have had been predisposed to increased
setup error, which could have led to undercoverage of the
clinical target volume, a subsequent increased risk of PSA
failure, and ultimately an earlier need for sAST. Strengths
of the study include that it was performed in a prospective
manner using pretreatment BMI data in the setting of a RCT
where specific guidelines existed for follow-up assessment
after the completion of initial treatment, minimizing the
possibility of ascertainment bias with respect to the primary
endpoint of time to sAST. Moreover a prespecified PSA level
of 10 ng/mL was used to determine when to initiate sAST, not
physician discretion, thereby strengthening the validity of the
association found between increasing BMI and earlier use of
sAST.
While it is not possible here to ascertain whether obesity
itself predisposes a man to the development of more aggres-
sive PC or whether factors that predispose a man to obesity
also predispose him to the development of aggressive PC, a
RCT could be envisaged that helps discern which of these
hypotheses is true. Such a studywould randomize overweight
or obese men at high risk of developing PC (e.g., due to
positive family history and/or African American ethnicity)
to a weight reduction intervention with targeted physical
activity, dietary recommendations, and monitoring of body
weight [28], versus no intervention. These patients would
be screened annually with serum PSA testing and a digital
rectal exam. Analysis would be performed of PC risk groups
at presentation and outcomes following standard treatment.
The primary endpoint would be the occurrence of high risk
disease between the two arms, with secondary endpoints
of PSA failure, time to sAST, death from PC, and all-
cause mortality. The results would enable a determination of
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whethermeasures shown to be effective in obesity prevention
[28] can reduce the risk ofmore aggressive PC at presentation
and adverse PC outcomes.
5. Conclusion
In conclusion, we found that increasing BMI was associated
with a shorter time to sAST following initial treatment with
RT or RT with six months of AST for unfavorable risk
PC. These results support the development of a RCT aimed
at identifying whether measures shown to be effective in
BMI reduction can reduce the incidence of high risk PC at
presentation and improve PC outcomes following treatment.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
References
[1] American Cancer Society, Cancer Facts & Figures, American
Cancer Society, Atlanta, Ga, USA, 2013.
[2] C. L. Ogden, M. D. Carroll, B. K. Kit, and K. M. Flegal,
“Prevalence of obesity in the United States, 2009-2010,” NCHS
Data Brief, no. 82, pp. 1–8, 2012.
[3] R. K. Masters, E. N. Reither, D. A. Powers et al., “The impact
of obesity on US mortality levels: the importance of age and
cohort factors in population estimates,” American Journal of
Public Health, vol. 103, no. 10, pp. 1895–1901, 2013.
[4] C. Haggstrom, T. Stocks, D. Ulmert et al., “Prospective study on
metabolic factors and risk of prostate cancer,” Cancer, vol. 118,
no. 24, pp. 6199–6206, 2012.
[5] J. Ma, H. Li, E. Giovannucci et al., “Prediagnostic body-mass
index, plasma C-peptide concentration, and prostate cancer-
specific mortality in men with prostate cancer: a long-term
survival analysis,”The Lancet Oncology, vol. 9, no. 11, pp. 1039–
1047, 2008.
[6] S. J. Freedland, W. J. Aronson, C. J. Kane et al., “Impact of
obesity on biochemical control after radical prostatectomy for
clinically localized prostate cancer: a report by the shared equal
access regional cancer hospital database study group,” Journal of
Clinical Oncology, vol. 22, no. 3, pp. 446–453, 2004.
[7] C. L. Amling, R. H. Riffenburgh, L. Sun et al., “Pathologic
variables and recurrence rates as related to obesity and race in
men with prostate cancer undergoing radical prostatectomy,”
Journal of Clinical Oncology, vol. 22, no. 3, pp. 439–445, 2004.
[8] S. S. Strom, A. M. Kamat, S. K. Gruschkus et al., “Influence of
obesity on biochemical and clinical failure after external-beam
radiotherapy for localized prostate cancer,” Cancer, vol. 107, no.
3, pp. 631–639, 2006.
[9] J. A. Efstathiou, M.-H. Chen, A. A. Renshaw, M. J. Loffredo,
and A. V. D’Amico, “Influence of body mass index on prostate-
specific antigen failure after androgen suppression and radia-
tion therapy for localized prostate cancer,” Cancer, vol. 109, no.
8, pp. 1493–1498, 2007.
[10] T. Zilli, M. Chagnon, T. Van Nguyen et al., “Influence of
abdominal adiposity, waist circumference, and bodymass index
on clinical and pathologic findings in patients treated with
radiotherapy for localized prostate cancer,” Cancer, vol. 116, no.
24, pp. 5650–5658, 2010.
[11] A. S. Parker, D. D. Thiel, E. Bergstralh et al., “Obese men have
more advanced and more aggressive prostate cancer at time of
surgery than non-obese men after adjusting for screening PSA
level and age: results from two independent nested case-control
studies,” Prostate Cancer and Prostatic Diseases, vol. 16, no. 4, pp.
352–356, 2013.
[12] E. Kheterpal, J. D. Sammon, M. Diaz et al., “Effect of metabolic
syndrome on pathologic features of prostate cancer,” Urologic
Oncology, vol. 31, no. 8, pp. 1054–1059, 2013.
[13] C. J. Keto, W. J. Aronson, M. K. Terris et al., “Obesity is
associated with castration-resistant disease and metastasis in
men treated with androgen deprivation therapy after radical
prostatectomy: results from the SEARCH database,” BJU Inter-
national, vol. 110, no. 4, pp. 492–498, 2012.
[14] C. De Nunzio, S. Albisinni, S. J. Freedland et al., “Abdominal
obesity as risk factor for prostate cancer diagnosis and high
grade disease: a prospective multicenter Italian cohort study,”
Urologic Oncology, vol. 31, no. 7, pp. 997–1002, 2013.
[15] V. Venkateswaran, A. Q. Haddad, N. E. Fleshner et al., “Associa-
tion of diet-induced hyperinsulinemia with accelerated growth
of prostate cancer (LNCaP) xenografts,” Journal of the National
Cancer Institute, vol. 99, no. 23, pp. 1793–1800, 2007.
[16] J. Caso, E. M. Masko, J. A. Ii et al., “The effect of carbohydrate
restriction on prostate cancer tumor growth in a castrate mouse
xenograft model,” Prostate, vol. 73, no. 5, pp. 449–454, 2013.
[17] T. Schnoeller, F. Jentzmik, L. Rinnab et al., “Circulating free
testosterone is an independent predictor of advanced disease in
patients with clinically localized prostate cancer,”World Journal
of Urology, vol. 31, no. 2, pp. 253–259, 2013.
[18] G. Williams, “Aromatase up-regulation, insulin and raised
intracellular oestrogens in men, induce adiposity, metabolic
syndrome and prostate disease, via aberrant ER-𝛼 and GPER
signalling,” Molecular and Cellular Endocrinology, vol. 351, no.
2, pp. 269–278, 2012.
[19] M. Okamoto, C. Lee, and R. Oyasu, “Interleukin-6 as a
paracrine and autocrine growth factor in human prostatic
carcinoma cells in vitro,” Cancer Research, vol. 57, no. 1, pp. 141–
146, 1997.
[20] P. L. Nguyen, J. Ma, J. E. Chavarro et al., “Fatty acid synthase
polymorphisms, tumor expression, body mass index, prostate
cancer risk, and survival,” Journal of Clinical Oncology, vol. 28,
no. 25, pp. 3958–3964, 2010.
[21] J. F. Piccirillo, R. M. Tierney, I. Costas, L. Grove, and E.
L. Spitznagel Jr., “Prognostic importance of comorbidity in a
hospital-based cancer registry,” Journal of the AmericanMedical
Association, vol. 291, no. 20, pp. 2441–2447, 2004.
[22] A. V. D’Amico, M.-H. Chen, A. A. Renshaw, M. Loffredo, and P.
W. Kantoff, “Androgen suppression and radiation vs radiation
alone for prostate cancer: a randomized trial,” Journal of the
AmericanMedical Association, vol. 299, no. 3, pp. 289–295, 2008.
[23] J. P. Klein and M. L. Moeschberger, “Semiparametric propor-
tional hazards regression with fixed covariates,” in Survival
Analysis: Techniques for Censored and TruncatedData, J. P. Klein
andM. L.Moeschberger, Eds., pp. 243–293, Springer, NewYork,
NY, USA, 2nd edition, 2003.
[24] E. L. Kaplan and P. Meier, “Non-parametric estimation from
incomplete observations,” Journal of the American Statistical
Association, vol. 53, pp. 457–481, 1958.
[25] R. J. Gray, “A class of K-sample tests for comparing the
cumulative incidence of a competing risk,” Annals of Statistics,
vol. 16, pp. 1141–1154, 1988.
6 Prostate Cancer
[26] “Simultaneous inferences and other topics in regression
analyses-1,” in Applied Linear Regression Models, J. Neter, W.
Wassermann, and M. Kutner, Eds., pp. 150–153, Richard D
Irwin, Homewood, Ill, USA, 1983.
[27] E. H. Allott, E. M. Masko, and S. J. Freedland, “Obesity and
prostate cancer: weighing the evidence,” European Urology, vol.
63, pp. 800–809, 2013.
[28] National Institutes of Health, “Clinical guidelines on the iden-
tification, evaluation, and treatment of overweight and obesity
in adults—the evidence report,” Obesity Research, vol. 6, article
464, 1998.
[29] M. H. Murphy, A. M. Nevill, E. M. Murtagh, and R. L. Holder,
“The effect of walking on fitness, fatness and resting blood
pressure: a meta-analysis of randomised, controlled trials,”
Preventive Medicine, vol. 44, no. 5, pp. 377–385, 2007.
[30] A. V. D’Amico, R. Whittington, S. B. Malkowicz et al., “Bio-
chemical outcome after radical prostatectomy, external beam
radiation therapy, or interstitial radiation therapy for clinically
localized prostate cancer,” Journal of the American Medical
Association, vol. 280, no. 11, pp. 969–974, 1998.
[31] N. L. Keating, A. J. O’Malley, and M. R. Smith, “Diabetes and
cardiovascular disease during androgen deprivation therapy for
prostate cancer,” Journal of Clinical Oncology, vol. 24, no. 27, pp.
4448–4456, 2006.
[32] M. Braga-Basaria, A. S. Dobs, D. C. Muller et al., “Metabolic
syndrome in men with prostate cancer undergoing long-term
androgen-deprivation therapy,” Journal of Clinical Oncology,
vol. 24, no. 24, pp. 3979–3983, 2006.
[33] L. E. Millender, M. Aubin, J. Pouliot, K. Shinohara, and M.
Roach III, “Daily electronic portal imaging for morbidly obese
men undergoing radiotherapy for localized prostate cancer,”
International Journal of Radiation Oncology Biology Physics, vol.
59, no. 1, pp. 6–10, 2004.
